The Latest Cardiac and Vascular News
Treatment with AT-001 normalizes cardiac energetics and improves cardiac function in a mouse model of Diabetic Cardiomyopathy (DbCM) NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high […]
Introducing a new portfolio of heart valve products aiming to restore health and extend life HONG KONG, Nov. 9, 2020 /PRNewswire/ — OrbusNeich and P+F today announced they have entered into an agreement for the exclusive distribution and manufacturing of a range of innovative minimally invasive heart valve products in the Asia Pacific region, including China, Japan, Taiwan, South […]
Matrix Plus promotes functional and structural maturation of hiPSC-CMs in seven days compared to partial maturation obtained within 30 to 100 days with current approaches SAN ANTONIO and ANN ARBOR, Mich., Nov. 9, 2020 /PRNewswire/ — StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) announced today the publication of research in Nature Scientific Reports demonstrating that CELLvo™ Matrix […]
Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session Cytokinetics to Host Investor/Media Event and Webcast Related to GALACTIC-HF Results on November 13, 2020 at 1:00 PM ET SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six presentations at the […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Food and Drug Administration (FDA) granted Impella 5.5 with SmartAssist its highest level of approval for safety and efficacy. In October 2019, the first U.S. patients were […]
TORRANCE, Calif., Nov. 5, 2020 /PRNewswire/ — HeartValveSurgery.com, a leading patient advocacy group for patients with heart valve disease, today released results of a new survey finding that most heart valve patients are “not very aware” of clinical trials, but most patients would consider enrolling in a clinical trial. The nationwide survey was […]
The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) during the high-risk 90-day period following a heart attack KING OF PRUSSIA, Pa., Nov. 5, 2020 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the study design manuscript for its landmark AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes II) has been […]
BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying mechanisms of cardiomyopathies. The MyoSeeds Program was founded […]
NIJMEGEN, Netherlands, Nov. 4, 2020 /PRNewswire/ — Saillant Therapeutics, an innovative preclinical stage biotechnology company developing promising small molecule-based therapies, today announced that it has obtained Proof of Concept for its lead compound (ST02) indicated for the treatment of heart failure. The compound was tested in a well-established preclinical heart failure model in which […]
CARLSBAD, Calif. and BOSTON, Nov. 3, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs). The study, Targeting ANGPTL3 with an antisense oligonucleotide in adults with dyslipidemia (TRANSLATE-TIMI […]
